Meridian Bioscience Reports 6 Percent Jump in Fiscal Q2 Sales | GenomeWeb

NEW YORK (GenomeWeb) — Meridian Biosciences today reported a 6 percent year-over-year increase in fiscal second quarter revenues as growth in its Illumigene molecular assay product portfolio helped temper flagging sales of its influenza immunoassay.

For the three months ended March 31, Meridian reported net sales of $50.1 million compared to $47.3 million in the year-ago period and falling short of the consensus analyst estimate of $52.2 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: certain genes repressed during memory formation, analysis of genomes from single neurons, and more.

NASA plans to test whether DNA sequencing studies can be conducted in microgravity.

Congress passes a continuing resolution to keep the US federal government funded through mid-December.

The Human Genome Project was launched 25 years ago, and at Nature, Francis Collins, James Watson, and Eric Green look back at the lessons learned.